CN110054637A - 一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合成方法 - Google Patents

一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合成方法 Download PDF

Info

Publication number
CN110054637A
CN110054637A CN201910503825.8A CN201910503825A CN110054637A CN 110054637 A CN110054637 A CN 110054637A CN 201910503825 A CN201910503825 A CN 201910503825A CN 110054637 A CN110054637 A CN 110054637A
Authority
CN
China
Prior art keywords
compound
catalyst
reaction
synthetic method
cdcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910503825.8A
Other languages
English (en)
Inventor
王震
王欣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chongqing University
Original Assignee
Chongqing University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing University filed Critical Chongqing University
Priority to CN201910503825.8A priority Critical patent/CN110054637A/zh
Publication of CN110054637A publication Critical patent/CN110054637A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

苯并磺内酰胺类化合物是一类非常重要的有机结构单元,普遍存在药物活性分子中,在全合成中也有广泛应用。本发明提供了一种通过联烯酮类化合物与苯并磺酰亚胺类化合物通过[4+2]环加成反应,构建苯并磺内酰胺类含手性四氢吡啶骨架的方法。该反应能够快速、高效地构建苯并磺内酰胺类含手性四氢吡啶骨架。本发明条件温和,操作简单,不需要进行无水无氧操作即可以高收率、高对映选择性的得到目标化合物,且底物适用范围广,产物应用价值高。

Description

一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合成 方法
技术领域
本发明属于有机合成方法学领域,涉及含季碳中心的苯并磺内酰胺类含四氢吡啶骨架的不对称合成方法。
背景技术
苯并磺内酰胺类化合物是一类非常重要的有机结构单元,普遍存在药物活性分子中,在全合成中也有广泛应用。近年来,苯并磺内酰胺类化合物在有机合成、药物化学、化学生物学等多个领域引起了广泛重视,发展高效的手性苯并磺内酰胺类合成方法,不仅有利于学科发展,也对新药研发和医药事业发展也有着重要意义。
2006年,Petry等人(US 7094794,2006-08-22)以2-氟5-硝基溴苄为底物,经过一系列反应得到噻唑一苯并异噻唑二氧化物类衍生物。此类化合物适合作为降血糖类药物用于糖尿病的预防和治疗。
2008年,Hanson课题组(Eur.J.Org.Chem.,2008,5254)首先报道了利用邻溴苯磺酰氯与苄胺、丙烯酸甲酯发生经典的Heck反应,再进行分子内的氮杂Michael加成反应得到1,1-二氧-1,2-苯并异噻唑-2-苄基-3-乙酸甲酯。然后用一锅法合成一系列3-取代-苯并五元磺内酰胺类化合物。
Tagliabue等人(J.Org.Chem.,2008,73:6686)使用链状五氟取代苯磺酰胺为起始物,使用固-液相转移催化剂进行分子内亲核取代反应实现关环制备苯并五元环内酰胺衍生物。
2014年,Li课题组(J.Org.Chem.,2014,79,8278)研究了取代苯磺酰胺与缺电子的单烯化合物在铑催化剂的作用下发生烯基化反应,选择性地生成单烯基产物或双烯基产物。
2015年,Liu课题组(Org.Chem.,2015,80,790)介绍了以N-乙酰基取代苯磺酰胺为底物,利用铑催化C-H烯基化反应合成3-单取代苯并磺内酰胺的方法。
2013年,Zhang课题(Synlett,2011,3,402)组报道了环状酮亚胺在三氟乙酸钯和手性配体的催化作用下,与芳基硼酸进行不对称加成反应,得到光学纯的3,3-二取代苯并磺内酰胺
虽然苯并磺内酰胺类的构建方法已有研究,但是通过联烯酮类化合物与苯并磺酰亚胺类化合物通过[4+2]环加成反应,构建具有手性中心的多取代苯并磺内酰胺类衍生物的研究还未见报导。
发明内容
苯并磺内酰胺类化合物是一类非常重要的有机结构单元,普遍存在药物活性分子中,在全合成中也有广泛应用。本发明提供了一种通过联烯酮类化合物与苯并磺酰亚胺类化合物通过[4+2]环加成反应,构建苯并磺内酰胺类含手性四氢吡啶骨架的方法。该反应能够快速、高效地构建苯并磺内酰胺类含手性四氢吡啶骨架。本发明条件温和,操作简单,不需要进行无水无氧操作即可以高收率、高对映选择性的得到目标化合物,且底物适用范围广,产物应用价值高。
本发明提供的合成苯并磺内酰胺类含四氢吡啶骨架衍生物的方法,其反应方程式如下:
其中R1为氢、甲基、甲氧基、叔丁基、氟、氯、三氟甲基、三氟甲氧基、苯基,R2为-COOEt,-COOMe,-COOBn,-COOiPr,-COPh,R3
所述的技术方案实施操作包括以下:将反应底物联烯酮化合物、苯并磺酰亚胺类化合物、催化剂和添加剂置于圆底烧瓶中加入一定量的合适溶剂,在一定温度下反应,TLC跟踪监测。待反应完成后,浓缩反应液,通过硅胶柱层析分离得到产物。
本发明所述的制备方法中,反应温度为0℃—25℃;优选0℃。
本发明所述的制备方法中,反应试剂组合物中催化剂优选1-6;最优选为:催化剂3。
本发明所述的制备方法中,反应试剂组合物中添加剂优选碳酸钠,碳酸钾,分子筛;最优选为:碳酸钠。
本发明所述的制备方法中,反应试剂组合物中催化剂3与底物的摩尔百分比优选为:催化剂3,10mol%-15mol%,最优选为:15mol%。
本发明所述的制备方法中,反应试剂组合物中添加剂与底物的摩尔百分比优选为:20mol%-100mol%,最优选为:40mol%。
本发明所述的制备方法中,反应溶剂优选为:二氯甲烷、氯仿、甲苯、乙酸乙酯、四氢呋喃、乙醚,最优选为:二氯乙烷。
本发明所述的制备方法中,底物浓度优选为:0.05-0.2mol/L,最优选为:0.1mol/L。
具体实施方式
本发明的任一实施方案中的监控方法是:薄层层析法。
结构确证技术手段均为本领域技术人员知晓的通用技术手段,核磁共振技术,高分辨质谱。
实施例1:
化合物1-1的制备
步骤:
准确称取苯并磺酰亚胺类化合物1a(23.9mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物1a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-1 41mg,收率95%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ7.87(d,J=7.6Hz,1H),7.67(t,J=7.5Hz,2H),7.63(t,J=7.1Hz,1H),7.59(d,J=8.3Hz,2H),7.42(d,J=8.3Hz,2H),6.66(d,J=4.6Hz,1H),4.68(d,J=17.7Hz,1H),4.30(d,J=18.8Hz,1H),4.27–4.11(m,2H),3.54(dd,J=17.9,5.1Hz,1H),2.59(dd,J=17.9,1.6Hz,1H),1.23(t,J=7.1Hz,3H).13C NMR(150MHz,CDCl3)δ189.2,165.0,134.8,133.2,131.8,131.3,130.7,129.8,129.3,126.6,126.6,124.8,119.6,117.7,59.8,59.1,32.9,30.0,10.0.HRMS(ESI),m/z calcd.forC21H19ClNO5S+([M+H]+)432.0672,found 432.0664。
旋光值:[α]25 D=-132.9;ee值:96%(HPLC条件:大赛璐IA柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-2的制备
步骤:
准确称取苯并磺酰亚胺类化合物2a(25.3mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物2a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-2 44.5mg,收率100%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(400MHz,CDCl3)δ7.87(d,J=7.4Hz,1H),7.67(t,J=6.1Hz,2H),7.64–7.54(m,2H),7.43(d,J=8.4Hz,2H),6.66(dd,J=4.2,1.8Hz,1H),5.02(dt,J=12.4,6.2Hz,1H),4.68(d,J=17.7Hz,1H),4.30(d,J=17.7Hz,1H),3.72–3.43(m,1H),2.58(dd,J=17.9,2.1Hz,1H),1.24(d,J=6.2Hz,3H),1.16(d,J=6.2Hz,3H).13C NMR(100MHz,CDCl3)δ193.1,168.4,138.7,137.1,137.0,135.8,135.3,134.8,133.1,13.2,130.5,128.7,123.4,121.6,71.2,71.1,63.9,36.9,33.9,21.5,21.3,21.28.HRMS(ESI),m/z calcd.for C22H21ClNO5S+([M+H]+)446.0829,found446.0822。
旋光值:[α]25 D=-32.7;ee值:96%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-3的制备
步骤:
准确称取苯并磺酰亚胺类化合物3a(22.5mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-3 41.7mg,收率100%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ7.88(d,J=7.5Hz,1H),7.73–7.62(m,3H),7.60(d,J=8.1Hz,2H),7.43(d,J=8.1Hz,2H),6.67(d,J=4.5Hz,1H),4.69(d,J=17.7Hz,1H),4.27(dd,J=21.7,12.5Hz,1H),3.77(s,3H),3.55(dd,J=17.9,5.0Hz,1H),2.60(d,J=17.9Hz,1H).13C NMR(150MHz,CDCl3)δ189.2,165.7,134.8,133.1,131.7,131.3,130.7,129.7,129.4,126.6,126.6,124.8,119.6,117.8,59.1,49.9,32.8,30.0.HRMS(ESI),m/z calcd.for C20H17ClNO5S([M+H]+)418.0516,found418.0508。
旋光值:[α]25 D=-141.9;ee值:(HPLC条件:大赛璐IA柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-4的制备
步骤:
准确称取苯并磺酰亚胺类化合物4a(30mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-4 45mg,收率97%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(400MHz,CDCl3)δ7.93–7.84(m,1H),7.64(dd,J=7.4,4.1Hz,3H),7.41(dd,J=21.2,8.2Hz,4H),7.28(s,4H),6.58(d,J=4.5Hz,1H),5.20(dd,J=49.6,12.1Hz,2H),4.70(d,J=17.7Hz,1H),4.25(d,J=17.7Hz,1H),3.52(dd,J=17.7,5.9Hz,1H),2.57(d,J=17.8Hz,1H).13C NMR(100MHz,CDCl3)δ192.9,169.0,138.7,137.0,135.4,135.2,134.7,134.6,133.9,133.3,130.6,130.5,128.7,128.25,123.6,121.7,68.5,63.9,36.9,34.1.HRMS(ESI),m/z calcd.forC26H19ClNNaO5S([M+Na]+)516.0648,found 516.0643。
旋光值:[α]25 D=-122.7;ee值:95%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-5的制备
步骤:
准确称取苯并磺酰亚胺类化合物5a(32.3mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-5 49mg,收率95%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ7.73(t,J=8.1Hz,1H),7.58(dd,J=12.3,8.1Hz,3H),7.46(d,J=8.2Hz,1H),7.43(d,J=8.3Hz,2H),6.66(d,J=4.4Hz,1H),4.68(d,J=17.6Hz,1H),4.29(td,J=14.6,7.3Hz,2H),4.17(dq,J=10.8,7.1Hz,1H),3.59–3.48(m,1H),2.61(dd,J=17.9,2.2Hz,1H),1.24(t,J=7.1Hz,3H).13C NMR(150MHz,CDCl3)δ193.1,168.6,143.9,138.9,138.7,136.8,135.2,135.2,134.7,130.6,128.8,125.7,122.9(q,J=273.4Hz),121.2,120.4,77.3,77.1,76.9,63.4,63.4,36.9,33.9,14.0.HRMS(ESI),m/z calcd.for C22H18ClF3NO6S([M+H]+)516.0495,found 516.0493。
旋光值:[α]25 D=-126.1;ee值:90%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-6的制备
步骤:
准确称取苯并磺酰亚胺类化合物6a(25.3mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-6 44.5mg,收率100%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ7.73(d,J=8.3Hz,1H),7.58(d,J=8.3Hz,2H),7.42(s,2H),7.41(s,1H),6.69–6.61(m,1H),4.65(d,J=17.7Hz,1H),4.34–4.20(m,2H),4.18–4.08(m,1H),3.50(dd,J=17.9,4.9Hz,1H),2.55(dd,J=18.0,2.0Hz,1H),2.47(s,3H),1.22(t,J=7.1Hz,3H).13C NMR(150MHz,CDCl3)δ188.4,164.5,139.7,133.9,132.5,131.3,130.5,130.0,126.7,126.3,125.8,123.9,118.9,116.7,58.9,58.3,32.0,29.2,17.1,9.2.HRMS(ESI),m/z calcd.for C22H21ClNO5S+([M+H]+)446.0829,found446.0821。
旋光值:[α]25 D=-422.2;ee值:95%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-7的制备
步骤:
准确称取苯并磺酰亚胺类化合物7a(25.3mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-7 44.5mg,收率100%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ7.66(s,1H),7.59(d,J=8.3Hz,2H),7.53(d,J=8.0Hz,1H),7.47(d,J=8.0Hz,1H),7.42(d,J=8.3Hz,2H),6.69–6.62(m,1H),4.67(d,J=17.7Hz,1H),4.35–4.21(m,2H),4.14(dd,J=10.7,7.1Hz,1H),3.52(dd,J=18.0,4.9Hz,1H),2.56(dd,J=17.9,1.9Hz,1H),2.48(s,3H),1.22(t,J=7.1Hz,3H).13C NMR(150MHz,CDCl3)δ188.5,164.5,136.6,134.0,132.5,130.6,130.0,129.5,129.0,128.3,125.8,123.9,118.5,116.9,58.9,58.3,32.1,29.3,16.6,9.3.HRMS(ESI),m/z calcd.for C22H21ClNO5S+([M+H]+)446.0829,found 446.0838。
旋光值:[α]25 D=-953.0;ee值:94%(HPLC条件:大赛璐IB柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-8的制备
步骤:
准确称取苯并磺酰亚胺类化合物8a(26.9mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-8 29mg,收率65%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ7.78(d,J=8.6Hz,1H),7.60(d,J=8.3Hz,2H),7.43(d,J=8.3Hz,2H),7.11(d,J=8.7Hz,1H),7.08(s,1H),6.65(d,J=4.6Hz,1H),4.66(d,J=17.8Hz,1H),4.40–4.23(m,2H),4.24–4.09(m,1H),3.90(s,3H),3.49(dd,J=17.9,5.2Hz,1H),2.71–2.51(m,1H),1.25(d,J=7.1Hz,2H),1.23(s,1H).13C NMR(150MHz,CDCl3)δ188.4,164.4,158.8,134.0,133.4,132.3,130.5,130.1,125.8,123.9,120.9,118.4,112.0,103.3,58.8,58.3,51.2,32.1,29.2,9.2.HRMS(ESI),m/z calcd.for C22H21ClNO6S+([M+H]+)462.0778,found 462.0771。
旋光值:[α]25 D=-137.1;ee值:96%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-9的制备
步骤:
准确称取苯并磺酰亚胺类化合物9a(27.2mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-9 40mg,收率86%。
黄色油状物,Rf=0.2(石油醚:乙酸乙酯=3:1).1H NMR(400MHz,CDCl3)δ7.81(d,J=8.2Hz,1H),7.66(s,1H),7.60(d,J=8.0Hz,3H),7.44(d,J=8.2Hz,2H),6.65(d,J=4.5Hz,1H),4.67(d,J=17.7Hz,1H),4.30(dd,J=10.7,7.0Hz,2H),4.24–4.13(m,1H),3.50(dd,J=17.8,5.5Hz,1H),2.61(d,J=17.7Hz,1H),1.26(t,J=7.0Hz,3H).13C NMR(100MHz,CDCl3)δ193.1,168.5,139.8,138.9,137.6,136.5,135.2,134.7,132.3,131.1,130.6,128.8,124.0,123.9,123.0,63.4,63.4,37.0,33.9,14.0.HRMS(ESI),m/z calcd.forC22H18Cl2NO5S+([M+H]+)466.0283,found 466.0266。
旋光值:[α]25 D=-121.7;ee值:95%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-10的制备
步骤:
准确称取苯并磺酰亚胺类化合物10a(25.7mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-10 31.8mg,收率71%。
黄色油状物,Rf=0.2(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ7.88(dd,J=8.5,4.6Hz,1H),7.60(d,J=8.4Hz,2H),7.44(d,J=8.4Hz,2H),7.39–7.29(m,2H),6.76–6.58(m,1H),4.67(d,J=17.7Hz,1H),4.39–4.25(m,2H),4.19(dd,J=10.8,7.1Hz,1H),3.49(ddd,J=17.9,6.3,1.8Hz,1H),2.62(dd,J=17.9,2.4Hz,1H),1.26(t,J=7.1Hz,3H).13C NMR(150MHz,CDCl3)δ193.2,168.7,166.2,164.5,138.9,138.8,138.8,136.6,135.2,134.8,130.6,129.9,128.8,124.2,124.2,118.7,118.5,111.3,111.2,63.5,37.1,33.9,14.0.HRMS(ESI),m/z calcd.for C21H17ClFNNaO5S([M+Na]+)472.0398,found472.0391。
旋光值:[α]25 D=-84.4;ee值:97%(UPC2条件:手性IA-3柱子,二氧化碳/甲醇=90:10,流速=1.0mL/min检测波长=245nm)。
化合物1-11的制备
步骤:
准确称取苯并磺酰亚胺类化合物11a(30.7mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-11 48mg,收率96%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ8.02(d,J=8.1Hz,1H),7.95(s,1H),7.92(d,J=8.1Hz,1H),7.60(d,J=8.4Hz,2H),7.51–7.39(m,2H),6.78–6.55(m,1H),4.70(d,J=17.6Hz,1H),4.33(tdd,J=14.2,10.5,4.0Hz,2H),4.19(dq,J=10.8,7.1Hz,1H),3.56(ddd,J=17.9,6.3,1.9Hz,1H),2.63(dd,J=17.9,2.5Hz,1H),1.25(t,J=7.1Hz,3H).13C NMR(151MHz,CDCl3)δ193.0,168.4,138.9,137.1,136.8,136.4,135.5,135.3,135.1,134.7,130.3,128.8,127.9,127.9,122.9(q,J=273.4Hz).122.7,121.2,121.1,63.7,63.5,37.0,33.9,13.9.HRMS(ESI),m/z calcd.forC22H17ClF3NNaO5S([M+Na]+)522.0366,found522.0367。
旋光值:[α]25 D=-123.9;ee值:95%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-12的制备
步骤:
准确称取苯并磺酰亚胺类化合物12a(29.5mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-12 40.6mg,收率82%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ7.81(d,J=8.3Hz,1H),7.68(dd,J=8.3,1.5Hz,1H),7.64–7.61(m,2H),7.61(s,1H),7.44(d,J=8.4Hz,2H),6.74–6.60(m,1H),4.68(d,J=17.7Hz,1H),4.45–4.23(m,2H),4.16(dd,J=10.8,7.1Hz,1H),3.55(ddd,J=17.9,6.3,1.9Hz,1H),2.61(dd,J=18.0,2.5Hz,1H),1.37(s,9H),1.24(t,J=7.1Hz,3H).13C NMR(150MHz,CDCl3)δ193.30,169.24,157.85,138.81,137.25,135.88,135.37,134.88,130.98,130.64,128.80,128.14,121.34,119.99,63.92,63.03,36.91,35.64,34.10,31.20,14.04.HRMS(ESI),m/z calcd.for C25H26ClNNaO5S([M+Na]+)510.1118,found 510.1108。
旋光值:[α]25 D=-931.3;ee值:80%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-13的制备
步骤:
准确称取苯并磺酰亚胺类化合物13a(28.9mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-13 47mg,收率98%。
黄色油状物,Rf=0.4(石油醚:乙酸乙酯=3:1).1H NMR(400MHz,CDCl3)δ8.48(d,J=8.2Hz,1H),8.12(d,J=8.5Hz,1H),7.98(d,J=8.1Hz,1H),7.75(t,J=7.5Hz,1H),7.71–7.64(m,1H),7.64–7.55(m,2H),7.43(d,J=8.2Hz,2H),6.70(d,J=4.5Hz,1H),4.79(d,J=17.6Hz,1H),4.36(d,J=17.7Hz,1H),4.31–4.20(m,1H),4.21–4.05(m,1H),3.62(dd,J=17.8,5.3Hz,1H),2.62(d,J=16.9Hz,1H),1.22(t,J=7.1Hz,3H).13C NMR(100MHz,CDCl3)δ193.2,169.1,138.8,137.2,135.3,134.9,134.7,134.4,133.8,130.6,129.5,129.1,128.7,128.3,125.3,123.2,119.0,118.9,77.3,77.1,76.7,63.8,63.2,36.9,33.9,13.9.HRMS(ESI),m/z calcd.for C25H21ClNO5S+([M+H]+)482.0829,found 482.0832。
旋光值:[α]25 D=-116.1;ee值:93.5%(HPLC条件:大赛璐IB柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-14的制备
步骤:
准确称取苯并磺酰亚胺类化合物14a(27.1mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-14 43mg,收率93%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(400MHz,CDCl3)δ8.02(d,J=7.3Hz,1H),7.73(d,J=7.8Hz,2H),7.66(dd,J=16.0,7.7Hz,2H),7.58(d,J=8.2Hz,2H),7.49(t,J=7.3Hz,1H),7.43(d,J=8.3Hz,2H),7.39–7.28(m,3H),6.78(d,J=4.5Hz,1H),4.70(d,J=18.9Hz,1H),3.74(dd,J=17.0,5.9Hz,2H),2.44(d,J=17.7Hz,1H).13CNMR(100MHz,CDCl3)δ195.1,193.4,139.5,138.6,137.4,135.3,133.8,133.7,133.0,132.4,130.6,129.1,128.6,128.6,123.1,122.7,68.2,36.9,32.6.HRMS(ESI),m/zcalcd.for C25H19ClNO4S+([M+H]+)464.0723,found 464.0720。
旋光值:[α]25 D=-250.8;ee值:90%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-15的制备
步骤:
准确称取苯并磺酰亚胺类化合物15a(28.9mg,0.1mmol),联烯酮化合物1(28mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物3a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-15 31.6mg,收率66%。
黄色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ8.03(d,J=7.7Hz,1H),7.87–7.80(m,2H),7.70(t,J=7.5Hz,1H),7.66(td,J=7.5,1.0Hz,1H),7.61–7.56(m,2H),7.43(d,J=8.4Hz,2H),7.34(d,J=7.6Hz,1H),7.00(t,J=8.6Hz,2H),6.81–6.74(m,1H),4.77–4.65(m,1H),3.77(dd,J=10.4,8.8Hz,1H),3.74–3.69(m,1H),2.51–2.36(m,1H).13C NMR(151MHz,CDCl3)δ193.5,193.2,139.5,138.7,137.3,135.3,133.9,132.9,132.3,132.3,130.8,130.6,129.8,128.7,123.1,122.9,116.0,115.9,68.2,36.9,32.58.HRMS(ESI),m/z calcd.for C25H18ClFNO4S+([M+H]+)482.0629,found482.0621。
旋光值:[α]25 D=-213.1;ee值:96.5%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-16的制备
步骤:
准确称取苯并磺酰亚胺类化合物1a(23.9mg,0.1mmol),联烯酮化合物2(32.4mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物1a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-16 43.7mg,收率96%。
黄色油状物,Rf=0.1(石油醚:乙酸乙酯=3:1).1H NMR(600MHz,CDCl3)δ8.17–8.02(m,2H),7.88(d,J=7.6Hz,1H),7.71–7.62(m,5H),7.73–7.59(m,5H),6.76–6.64(m,1H),4.70(dt,J=17.7,2.0Hz,1H),4.38–4.23(m,2H),4.16(dq,J=10.8,7.1Hz,1H),3.94(s,3H),3.55(ddd,J=18.0,6.3,1.9Hz,1H),2.60(ddd,J=18.0,5.7,3.1Hz,1H),1.23(t,J=7.1Hz,3H).13C NMR(150MHz,CDCl3)δ193.9,169.0,166.2,140.8,138.4,135.8,134.9,133.8,133.4,133.2,130.6,129.6,129.0,123.6,121.7,63.8,63.2,52.5,36.8,34.1,14.0.HRMS(ESI),m/z calcd.for C23H21ClNNaO7S([M+Na]+)478.0936,found 478.0934。
旋光值:[α]25 D=-121.1;ee值:97%(HPLC条件:大赛璐IB柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
化合物1-17的制备
步骤:
准确称取苯并磺酰亚胺类化合物1a(23.9mg,0.1mmol),联烯酮化合物3(44.5mg,0.15mmol),催化剂3(9.4mg,0.015mmol)和添加剂碳酸钠(4.2mg,0.004mmol)置于装有搅拌子的10mL反应试管中,加入1mL二氯乙烷并在0℃下反应,TLC监测直到苯并磺酰亚胺类化合物1a反应完全。直接将反应液浓缩,用柱层析法分离纯化,得到产物1-17 49.2mg,收率93%。
白色油状物,Rf=0.3(石油醚:乙酸乙酯=3:1).1H NMR(400MHz,CDCl3)δ8.18(d,J=7.5Hz,2H),8.12(d,J=8.0Hz,2H),8.02(s,2H),7.89(d,J=7.5Hz,2H),7.70(d,J=3.9Hz,3H),7.65(dt,J=11.8,4.0Hz,2H),7.43–7.31(m,4H),6.91–6.79(m,2H),4.73(d,J=17.5Hz,2H),4.39(d,J=17.6Hz,2H),4.30(ddd,J=14.2,10.7,7.1Hz,2H),4.17(ddd,J=14.2,10.8,7.1Hz,2H),3.57(dd,J=17.6,5.1Hz,2H),2.62(dd,J=17.6,1.9Hz,3H),1.70(s,18H),1.26(t,J=7.1Hz,6H).13C NMR(100MHz,CDCl3)δ188.7,169.1,149.1,136.5,135.8,135.4,133.8,133.3,132.8,132.3,132.3,130.5,127.9,125.8,124.3,123.5,122.2,121.6,118.4,115.1,85.6,64.0,63.1,37.04,33.94,28.08,14.0.HRMS(ESI),m/zcalcd.for C22H28N2NaO7S([M+Na]+)559.1515,found 559.1511.
旋光值:[α]25 D=-48.7;ee值:75%(HPLC条件:大赛璐AD-H柱子,正己烷/异丙醇=70:30,流速=0.8mL/min,检测波长=245nm)。
在此说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管通过参照本发明的优选实施例已经对本发明进行了描述,但本领域的普通技术人员应当理解,可以在形式上和细节上对其做出各种各样的改变,而不偏离本发明的精神和范围。

Claims (8)

1.本发明提供的一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合方法,其反应方程式如下:
其中R1为氢、甲基、甲氧基、叔丁基、氟、氯、三氟甲基、三氟甲氧基、苯基,R2为-COOEt,-COOMe,-COOBn,-COOi-Pr,-COPh,R3其特征在于使用手性膦催化剂催化反应。
2.如权利要求1所述的合成方法,其特征在于,反应试剂组合物中催化剂为1-6。
3.如权利要求1所述的合成方法,其特征在于,反应温度为0℃—25℃。
4.如权利要求1所述的合成方法,其特征在于,反应试剂组合物中添加剂优选碳酸钠,碳酸钾,分子筛。
5.如权利要求1所述的合成方法,其特征在于,反应试剂组合物中催化剂3与底物的摩尔百分比优选为:催化剂3,,10mol%-15mol%。
6.如权利要求1所述的合成方法,其特征在于,反应试剂组合物中添加剂与底物的摩尔百分比优选为:20mol%-100mol%。
7.如权利要求1所述的合成方法,其特征在于,反应溶剂优选为:二氯甲烷、氯仿、甲苯、乙酸乙酯、四氢呋喃、乙醚。
8.如权利要求1所述的合成方法,其特征在于,底物浓度优选为:0.05-0.2mol/L。
CN201910503825.8A 2019-06-11 2019-06-11 一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合成方法 Pending CN110054637A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910503825.8A CN110054637A (zh) 2019-06-11 2019-06-11 一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合成方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910503825.8A CN110054637A (zh) 2019-06-11 2019-06-11 一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合成方法

Publications (1)

Publication Number Publication Date
CN110054637A true CN110054637A (zh) 2019-07-26

Family

ID=67325749

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910503825.8A Pending CN110054637A (zh) 2019-06-11 2019-06-11 一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合成方法

Country Status (1)

Country Link
CN (1) CN110054637A (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112830957A (zh) * 2021-01-07 2021-05-25 江西师范大学 一种高效制备卡非佐米的方法
CN115010649A (zh) * 2022-06-30 2022-09-06 商丘师范学院 一种C-N轴手性苯并[c]咔唑类化合物及其合成方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHINOBU TAKIZAWA ET AL.: "Enantioselective Organocatalyzed Formal [4+2] Cycloaddition of Ketimines with Allenoates: Easy Access to a Tetrahydropyridine Framework with a Chiral Tetrasubstituted Stereogenic Carbon Center", 《ASIAN J. ORG. CHEM.》 *
XIANG-YU CHEN ET AL.: "Phosphane-Catalyzed [4+2] Annulation of Allenoates with Ketimines: Synthesis of Sultam-Fused Tetrahydropyridines", 《EUR.J.ORG.CHEM.》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112830957A (zh) * 2021-01-07 2021-05-25 江西师范大学 一种高效制备卡非佐米的方法
CN115010649A (zh) * 2022-06-30 2022-09-06 商丘师范学院 一种C-N轴手性苯并[c]咔唑类化合物及其合成方法
CN115010649B (zh) * 2022-06-30 2023-08-25 商丘师范学院 一种C-N轴手性苯并[c]咔唑类化合物及其合成方法

Similar Documents

Publication Publication Date Title
Ju et al. Silver-catalyzed enantioselective propargylic C–H bond amination through rational ligand design
France et al. Advances in the catalytic, asymmetric synthesis of β-lactams
Feldman et al. Alkynyliodonium salts in organic synthesis. Development of a unified strategy for the syntheses of (−)-agelastatin A and (−)-agelastatin B
Holder et al. Synthesis of diverse β-quaternary ketones via palladium-catalyzed asymmetric conjugate addition of arylboronic acids to cyclic enones
CN110054637A (zh) 一种制备苯并磺内酰胺类含手性四氢吡啶骨架的不对称合成方法
de Vries et al. Diastereoselective synthesis of pyridyl substituted thiazolidin-4-ones. New ligands for the Cu (I) catalyzed asymmetric conjugate addition of diethylzinc to enones
Desrosiers et al. Enantioselective synthesis of β-amino alcohols and α-amino acids via a copper catalyzed addition of diorganozinc reagents to N-phosphinoylimines
Chen et al. Metal-free intramolecular carbocyanation of activated alkenes: functionalized nitriles bearing β-quaternary carbon centers.
Couty et al. 2‐Cyanoazetidines and Azetidinium Ions: Scaffolds for Molecular Diversity
CN104744394B (zh) 一种不对称合成含三氟甲基手性季碳化合物的方法
Alcaide et al. A Novel One‐Step Approach for the Preparation of α‐Amino Acids, α‐Amino Amides, and Dipeptides from Azetidine‐2, 3‐diones
CN107337663B (zh) 一种可见光诱导3-硫代螺环三烯酮化合物的制备方法
Ying et al. Green and efficient Knoevenagel condensation catalysed by a DBU based ionic liquid in water
JP2003527445A (ja) 不飽和有機化合物のメタセシス反応を実施するための方法
Asano Multipoint recognition of molecular conformations with organocatalysts for asymmetric synthetic reactions
CN114105860A (zh) 一种手性氧化吲哚螺环类似物的催化不对称合成方法及应用
Chen et al. Enantioselective Michael addition of 3-ethyl carboxylate substituted pyrazolones to 5-alkenyl thiazolones catalyzed by squaramide organocatalyst
Gizecki et al. Novel use of N-benzoyl-N, O-acetals as N-acylimine equivalents in asymmetric heterocycloaddition: An extended enantioselective pathway to β-benzamido aldehydes
Tozawa et al. Enantioselective synthesis of 3, 4-dihydropyran-2-ones by chiral quaternary ammonium phenoxide-catalyzed tandem Michael addition and lactonization
Tsou et al. Enantioselective organocatalytic vinylogous aldol-cyclization cascade reaction of 3-alkylidene oxindoles with o-quinones
Peng et al. BODIPY Photocatalyzed Beckmann rearrangement and hydrolysis of Oximes under visible light
Wang et al. Highly Enantioselective Synthesis of (Diarylmethyl) amines by Rhodium-Catalyzed Arylation of N-Nosylimines Using a Chiral Bicyclo [3.3. 0] diene Ligand
Tung et al. Synthesis of spirolactams and fused bicyclic lactams via acid-promoted cyclolactamization of (ethynyl (tosyl) amino) methyl-tethered cyclohex-2-enols
CN110156815A (zh) 12a氢-苯并[f]吡啶[1,2-d][1,4]硫氮卓及其制备方法
CN109251192B (zh) 3位或4位三氟甲基取代异香豆素的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190726

WD01 Invention patent application deemed withdrawn after publication